TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant completed the 52-week treatment period in Study M15-562 (NCT02985879)~* In the opinion of the investigator, the participant was compliant during participation in Study M15-562 (NCT02985879)~* Participant has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend)~Exclusion Criteria:~* Participants who weigh less than 44 kg (97 lbs) at the time of study entry~* Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI)~* Participant has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results~* More than 8 weeks have elapsed since the participant received his/her last dose of study drug in Study M15-562 (NCT02985879)~* Participant is considered by the investigator, for any reason, to be an unsuitable candidate to receive ABBV-8E12 or the participant is considered by the investigator to be unable or unlikely to comply with the dosing schedule or study evaluations

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- M15-562 ABBV-8E12 2000 mg/M15-563 ABBV-8E12 2000 mg (Type: EXPERIMENTAL): Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
- M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg (Type: EXPERIMENTAL): Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
- M15-562 Placebo/M15-563 ABBV-8E12 2000 mg (Type: EXPERIMENTAL): Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
- M15-562 Placebo/M15-563 ABBV-8E12 4000 mg (Type: EXPERIMENTAL): Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Darbepoetin Alfa and Anemia of Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* nonmyeloid malignancies (including lymphocytic leukemias)~* anemia (hemoglobin concentration less than or equal to 11.0 g/dL) due to cancer and/or previous chemotherapy or radiotherapy~* Eastern Cooperative Oncology Group performance status of 0 to 2~* adequate liver and renal functions~* 18 years or older~Exclusion Criteria:~* history of recombinant human erythropoietin therapy, cytotoxic chemotherapy, or more than 30 Gy radiotherapy to the whole pelvis within 4 weeks before screening~* acute myelogenous leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome~* known hematologic disorders that could cause anemia~* inflammatory or cardiac disorders~* previous positive antibody response to any erythropoietic agent~* history of pure red cell aplasia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational Group (Type: OTHER): Participants in the observation group were evaluated once every 2 weeks for the first 12 weeks (test period). No darbepoetin alfa was administered to the observation group during this period. Darbepoetin alfa could be initiated at a dose of 3.0 μg/kg once every 2 weeks beginning with the first visit after the test period at which the participants hemoglobin concentration was less than or equal to 11.0 g/dL. The dose of darbepoetin alfa could be increased to 5.0 μg/kg once every 2 weeks after 6 weeks of darbepoetin alfa treatment in participants with a hemoglobin change from baseline of less than 1.0 g/dL.
- 21 week treatment group (Type: ACTIVE_COMPARATOR): Participants in the treatment group received darbepoetin alfa subcutaneously (SC) at a dose of 3.0 μg/kg once every 2 weeks for 21 weeks. The dose of darbepoetin alfa could be increased at week 7 (to 5.0 μg/kg once every 2 weeks) or at week 13 (to 9.0 μg/kg once every 2 weeks) in participants with a hemoglobin change from baseline of less than 1.0 g/dL who dose escalated at week 7.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Risperidone and Zotepine in the Treatment of Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients may be included in the study if they meet all of the following criteria:DSM-IV-TR delirium (293.0 delirium due to general medical condition, 290.3 dementia with delirium 290.41, arteriosclerotic dementia with delirium 780.09delirium NOS. 292.8 substance-induced delirium( excluding alcohol and BZD)~* Age 18 to 85 year-old inpatients; either sex~* Patients are able to take Risperidone or Zotepine orally~Exclusion Criteria:~* Alcohol-induced delirium; delirium caused by seizures; Sedative, hypnotic or anxiolytic withdrawal delirium~* Patients with schizophrenia or bipolar disorder or being treated with antipsychotics~* Patients are mandatory to take parenteral treatments~* Patients are known to be allergic to Risperidone or Zotepine~* Women with pregnancy or during lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): zotepine , start from 50mg/day then titrate according to individual case
- 2 (Type: ACTIVE_COMPARATOR): Risperidone, start from 1mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Needle-Free Injections of Gonadotropins for Superovulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing their first cycle of superovulation~* Age 18-39~* BMI 18-35 kg/m2~* Uterine cavity evaluation (hysterosalpingogram, sonohysterogram, hysteroscopy) normal in the preceding 6 or 12 months~* Early follicular phase (Day 2 or Day 3) serum FSH \<12 IU/L in the preceding 12 months~* Subject able to give informed consent~* At least 1 patent fallopian tube~* One semen analysis in the prior 12 months with total motile count \> 10M~Exclusion Criteria:~* Prior enrollment in this study~* Any prior early follicular phase serum FSH level ≥12 IU/L~* Previous ovarian stimulation with gonadotropins~* Diabetes mellitus or uncontrolled thyroid disease~* Abnormal uterine cavity, such as unresected submucosal fibroids, uterine septum, Mullerian anomaly such as bicornuate or unicornuate uterus or intrauterine adhesions~* Hydrosalpinx

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Needle free system (Type: EXPERIMENTAL): Intervention will consist of the gonadotropin BRAVELLE being injected using the Comfort-in™ needle free system for the duration of a standard superovulation cycle
- Standard needle injection system (Type: ACTIVE_COMPARATOR): Control patients will undergo their superovulation cycle using the gold standard subcutaneous needle injection system for their gonadotropin injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reliability of 6-Minutes Walking Test in Hip Fracture Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 60 years or above~* Hip fracture patients with a Intra - or Extra Capsular hip fracture~* Testing within 3 - 5 weeks postsurgery in an outpatient facility~* No weightbearing restrictions on the fractured limb~* Normal cognitive level (Mini Mental State Examination(MMSE) - score ≥20 points)~* Participants should not experiencing hip related pain more or less than moderate according to Verbal Ranking Scale when resting~* To have the ability to write and understand danish language~Exclusion Criteria:~- MMSE score ≤19 points

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 6 minutes walking test (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age~* Male or female patients (females of child-bearing potential must have been surgically sterilized or use a reliable method of contraception).~* Patients undergoing complex\* cardiac surgery on CPB and having systolic PAP \> 40 mmHg or mean PAP \> 30 mmHg (\*surgery on 2 valves, 1 valve and revascularization, or reoperation of a valve)~* Patients undergoing cardiac surgery on CPB and having pre-operative pulmonary hypertension due to left heart disease with systolic PAP \> 60 mmHg~* Signed written informed consent~Exclusion Criteria:~* Systolic blood pressure \< 100 mmHg~* Significant chronic lung disease~* Emergency surgery~* Pregnant/breast-feeding~* Investigational drug use within 28 days prior to randomization~* Complex adult congenital heart disease.~* Severe concomitant illness limiting life expectancy to \< 6 months~* Participation in a device study that will affect the outcome of the study~* Pre-operative use of balloon pump, inotropes/vasopressors, treatment of pulmonary arterial hypertension~* Known hypersensitivity to tezosentan or drugs of the same class, or any of their excipients~* Severe liver impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Tezosentan
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed malignant melanoma or renal cell carcinoma~* At stage IV or relapse~* At least one prior chemotherapy including targeted agents~* At least one haploidential or partially matched-HLA donor~* ECOG performance status 0-1~* Age 18-75 years~* Measurable lesion~* Adequate bone marrow, liver, and renal functions~Exclusion Criteria:~* Chemotherapy within 4 weeks~* Stem cell transplantation~* Active CNS metastasis~* Hypersensitivity to IL-2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- High-dose IL-2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fetal Electrocardiogram Extraction-Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be pregnant women at least 18 years of age.~* Subject's fetus must be between the gestational ages of 16 weeks and term.~* Subjects must be able to tolerate 20 minutes (per fetus for which trans-abdominal ECG and Doppler ultrasounds will be performed) in the supine position.~* Subjects are willing to provide informed consent and are willing to participate in all procedures necessary to complete the study.~Exclusion Criteria:~* Subjects must not have a physical or mental condition, in the opinion of the investigator, which will limit their ability to provide adequate consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pregnancy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Probuphine in Patients With Opioid Dependence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients must meet the following eligibility criteria:~* Expected to complete 24 weeks of treatment in PRO-807 or PRO-808~* Voluntarily provide written informed consent prior to the conduct of any study-related procedures~* Deemed appropriate for entry into this re-treatment study by the Investigator~* Females of childbearing potential and fertile males must use a reliable means of contraception~Exclusion Criteria:~Patients are not eligible for enrollment if any of the following criteria are met:~* Presence of aspartate aminotransferase (AST) levels ≥ 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels ≥ 3 X upper limit of normal and/or total bilirubin ≥ 1.5 X upper limit of normal and/or creatinine ≥ 1.5 X upper limit of normal, measured at the time of the Week 20 Visit for the previous trial (PRO-807 or PRO-808), or any time less than 5 weeks prior to the Implant Visit.~* Current diagnosis of chronic pain requiring opioids for treatment~* Pregnant or lactating females~* Current use of agents metabolized through cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)~* Current history of coagulopathy and anti-coagulant therapy (such as warfarin)~* Current use of benzodiazepines other than physician prescribed use~* Significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigator, would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent~* Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Probuphine (Type: EXPERIMENTAL): buprenorphine implant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Colonography Versus Colonoscopy in High Risk Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Surveillance of patients with a personal history of advanced adenoma or CRC:~* Informed consent obtained~* Age ≥ 18 and ≤ 80 years old~* History of advanced adenomatous polyps~* Or history of non metastatic CRC with curative surgery and without other treatment more than 2 years before enrollment.~* Previous medical examination~Screening of patients with a Family history of CRC at high risk:~* Informed consent obtained~* Age ≥ 18 and ≤ 80 years old~* First degree family history of colorectal cancer diagnosed \<60yrs during the five previous years-Previous medical examination~Exclusion Criteria:~Personal histories~* Age \< 18 or \>80 years old~* history of non adenomatous polyps~* history of Metastatic CRC~* familial adenomatous polyposis, Peutz-Jeghers syndrome, hereditary non polyposis colorectal cancer (HNPCC), juvenile polyposis syndrome~* Familial history of familial adenomatous polyposis~* Personal history of subtotal colectomy (but not of hemicolectomy, to confer to inclusion criteria)~* Colonoscopy with a polyps resection dated more than 5 years and less than 2 years prior to enrollment.~* Enrollment in another protocol~* no health insurance affiliation Family histories~* Age \< 18 or \>80 years old~* Patients with one or several family histories of first degree colorectal cancer occured to unknown age or diagnosed after 60 years old.~* Eligible patients having already undergone colonoscopy screening~* no health insurance affiliation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): CT Colonography
- 2 (Type: ACTIVE_COMPARATOR): Colonoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COMO: Cognition Study With HIV+ Patients (CTNPT 015)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* are 18 years and older~* have the capacity to give informed consent as determined by the research nurse~* have unexplained cognitive decline (reported either by the patient or an outside informant)~* have been on a stable ART regimen for \> 6 months~* have an undetectable viral load in plasma for at least 6 months (a single blip of ≤ 150 copies/mL will be accepted)~* have not had a change in medications that could potentially interfere with cognition in the past 4 months~Exclusion Criteria:~* detectable VL in the plasma~* past history of dementia~* past history of Central Nervous System opportunistic infection or stroke~* current substance abuse ( as per DSM-IV criteria) other than cigarettes~* coagulopathy~* thrombocytopenia~* use of Coumadin~* intra-cranial hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Change in ARVs to improve cognition (Type: EXPERIMENTAL): Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Care of Oncological Patients With HPN

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women with an initial prescription for HPN during the current hospital stay~* Planned PN must at least contain the macronutrients glucose and amino acids.~* Solid, malignant tumor~* Anticipated duration of the HPN is at least 28 days~* Age ≥18 years~* Full legal capacity or legal guardian available~* Fluent in German language~* Able to read and write in German language~* Signed patient informed consent form~* Indication for PN~Exclusion Criteria:~* Contraindication for PN~* ECOG performance status \>3~* Pregnant and breast-feeding women~* Concurrent participation in another clinical study that requires deviations from the hospital's routine PN, nutrition and/or nursing procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Comparison of the Use of JET and Conventional Ventilation in Pulmonary Vein Isolation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* paroxysmal or persistent AF, first time PVI or left atrial procedure~Exclusion Criteria:~* repeat procedure~* any contraindications to receiving JET ventilation in the judgement of the treating anesthesiologist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Conventional Ventilation (Type: PLACEBO_COMPARATOR): Patients receiving conventional ventilation for the duration of this study
- Jet Ventilation (Type: ACTIVE_COMPARATOR): Patients receiving Jet ventilation while under general anesthesia and during mapping and ablation in the left atrium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues